Literature DB >> 16395265

Increased plasma protein homocysteinylation in hemodialysis patients.

A F Perna1, E Satta, F Acanfora, C Lombardi, D Ingrosso, N G De Santo.   

Abstract

Hyperhomocysteinemia, an independent cardiovascular risk factor, is present in the majority of hemodialysis patients. Among the postulated mechanisms of toxicity, protein homocysteinylation is potentially able to cause significant alterations in protein function. Protein homocysteinylation occurs through various mechanisms, among which is the post-translational acylation of free amino groups (protein-N-homocysteinylation, mediated by homocysteine (Hcy) thiolactone). Another type of protein homocysteinylation occurs through the formation of a covalent -S-S- bond, found primarily with cysteine residues (protein-S-homocysteinylation). Scant data are available in the literature regarding the extent to which alterations in protein homocysteinylation are present in uremic patients on hemodialysis, and the effects of folate treatment are not known. Protein homocysteinylation was measured in a group of hemodialysis patients (n=28) compared to controls (n=14), with a new method combining protein reduction, gel filtration and Hcy derivatization. Chemical hydrolysis was performed, followed by high-pressure liquid chromatography separation. The effects of folate treatment on protein homocysteinylation, as well as in vitro binding characteristics were evaluated. Plasma Hcy, protein-N-homocysteinylation and protein-S-homocysteinylation were significantly higher in patients vs controls. Plasma Hcy and protein-S-homocysteinylation were significantly correlated. After 2 months of oral folate treatment, protein-N-homocysteinylation was normalized, and protein-S-homocysteinylation was significantly reduced. Studies on albumin-binding capacity after in vitro homocysteinylation show that homocysteinylated albumin is significantly altered at the diazepam-binding site. In conclusion, increased protein homocysteinylation is present in hemodialysis patients, with possible consequences in terms of protein function. This alteration can be partially reversed after folate treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16395265     DOI: 10.1038/sj.ki.5000070

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  20 in total

Review 1.  Normal and pathologic concentrations of uremic toxins.

Authors:  Flore Duranton; Gerald Cohen; Rita De Smet; Mariano Rodriguez; Joachim Jankowski; Raymond Vanholder; Angel Argiles
Journal:  J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 10.121

Review 2.  Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties.

Authors:  K Oettl; R E Stauber
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

3.  Characterization of N-homocysteinylated albumin adducts.

Authors:  Valeria Genoud; Mercedes Castañon; Ana María Lauricella; Irene Quintana
Journal:  Protein J       Date:  2014-02       Impact factor: 2.371

Review 4.  Mechanisms of homocysteine-induced glomerular injury and sclerosis.

Authors:  Fan Yi; Pin-Lan Li
Journal:  Am J Nephrol       Date:  2007-11-07       Impact factor: 3.754

5.  Homocystamides promote free-radical and oxidative damage to proteins.

Authors:  Martha Sibrian-Vazquez; Jorge O Escobedo; Soojin Lim; George K Samoei; Robert M Strongin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-18       Impact factor: 11.205

6.  N- and S-homocysteinylation reduce the binding of human serum albumin to catechins.

Authors:  Angelo Zinellu; Salvatore Sotgia; Bastianina Scanu; Dionigia Arru; Annalisa Cossu; Anna Maria Posadino; Roberta Giordo; Arduino A Mangoni; Gianfranco Pintus; Ciriaco Carru
Journal:  Eur J Nutr       Date:  2015-12-10       Impact factor: 5.614

Review 7.  Homocysteine in renovascular complications: hydrogen sulfide is a modulator and plausible anaerobic ATP generator.

Authors:  Utpal Sen; Sathnur B Pushpakumar; Matthew A Amin; Suresh C Tyagi
Journal:  Nitric Oxide       Date:  2014-06-22       Impact factor: 4.427

8.  Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure.

Authors:  Ken-ichi Fujita; Yusuke Masuo; Hidenori Okumura; Yusuke Watanabe; Hiromichi Suzuki; Yu Sunakawa; Ken Shimada; Kaori Kawara; Yuko Akiyama; Masanori Kitamura; Munetaka Kunishima; Yasutsuna Sasaki; Yukio Kato
Journal:  Pharm Res       Date:  2015-09-03       Impact factor: 4.200

9.  Genetic or nutritional disorders in homocysteine or folate metabolism increase protein N-homocysteinylation in mice.

Authors:  Hieronim Jakubowski; Joanna Perla-Kaján; Richard H Finnell; Robert M Cabrera; Hong Wang; Sapna Gupta; Warren D Kruger; Jan P Kraus; Diana M Shih
Journal:  FASEB J       Date:  2009-02-09       Impact factor: 5.191

10.  Homocysteinylated protein levels in internal mammary artery (IMA) fragments and its genotype-dependence. S-homocysteine-induced methylation modifications in IMA and aortic fragments.

Authors:  Francisco Rodríguez-Esparragón; Jaime Alberto Serna-Gómez; Erika Hernández-Velázquez; Nisa Buset-Ríos; Yaridé Hernández-Trujillo; Miguel A García-Bello; José C Rodríguez-Pérez
Journal:  Mol Cell Biochem       Date:  2012-07-14       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.